Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in north Indian population

DNA and Cell Biology

Volumn 29, Issue 7, 2010, Pages 349-356

  Gangwar, Ruchika ^a   Mittal, Rama Devi ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; FAS ANTIGEN; PROTEIN MDM2;

ADULT; AGED; APOPTOSIS; ARTICLE; BCG VACCINATION; BLADDER CANCER; CANCER INVASION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE INTERACTION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

APOPTOSIS; BCG VACCINE; CELL CYCLE; CONTINENTAL POPULATION GROUPS; CYCLIN D1; GENES; GENOTYPE; HUMANS; INDIA; MYCOBACTERIUM BOVIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POPULATION GROUPS; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

MYCOBACTERIUM BOVIS BCG;

EID: 77954912151     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2009.0982     Document Type: Article

References (31)

1. Betticher, D.C., Thatcher, N., Altermatt, H.J., Hoban, P., Ryder, W.D., and Heighway, J. (1995). Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11, 1005-1011.
2. Bevers, R.F.M., Kurth, K.H., and Schamhart, D.H.J. (2004). Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer 91, 607-612.
3. Bond, G.L., Hu, W., Bond, E.E., Robins, H., Lutzker, S.G., Arva, N.C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., Onel, K., Yip, L., Hwang, S.J., Strong, L.C., Lozano, G., and Levine, A.J. (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119, 591-602.
4. Brown, D.R., Thomas, C.A., and Deb, S.P. (1998). The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J 17, 2513-2525.
5. Colombel, M., Soloway, M., and Akaza, H. (2008). Epidemiology, staging, grading and risk stratification of bladder cancer. Eur Urol Suppl 7, 618-626.
6. Cortessis, V.K., Siegmund, K., Xue, S., Ross, R.K., and Yu, M.C. (2003). A case-control study of cyclin D1 CCND1 870A?G polymorphism and bladder cancer. Carcinogenesis 24, 1645-1650.
7. Freedman, D.A., Wu, L., and Levine, A.J. (1999). Functions of the MDM2 oncoprotein. Cell Mol Life Sci 5, 96-107.
8. Gupta, V.K., Feber, A., Xi, L., Pennathur, A., Wu, M., Luketich, J.D., and Godfrey, T.E. (2008). Association between CCND1 G=A870 polymorphism, allele-specific amplification, Cyclin D1 expression, and survival in esophageal and lung carcinoma. Clin Cancer Res 14, 7804-7812.
9. Hirata, H., Hinoda, Y., Kikuno, N., Kawamoto, K., Suehiro, Y., Tanaka, Y., and Dahiya, R. (2007). MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res 13, 4123-4129.
10. Hong, Y., Miao, X., Zhang, X., Ding, F., Luo, A., Guo, Y., Tan, W., Liu, Z., and Lin, D. (2005). The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 65, 9582-9587.
11. Hosokawa, Y., and Arnold, A. (1998). Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele-specific expression. Genes Chromosomes Cancer 22, 66-71.
12. Hu, Y., Xu, Y., Wang, Y., Ouyang, T., Li, J.F., Wang, T.F., Fan, Z.Q., Fan, T., Lin, B.Y., Geng, P.L., and Xie, Y.T. (2009). Prognostic role of apoptosis-related gene Fas-1377 and-670 polymorphisms in breast cancer. Zhonghua Zhong Liu Za Zhi 31, 104-107.
13. Ito, M., Habuchi, T., Watanabe, J., Higashi, S., Nishiyama, H., Wang, L., Tsuchiya, N., Kamoto, T., and Ogawa, O. (2004). Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer. Urology 64, 74-78.
14. Jain, M., Kumar, S., Lal, P., Tiwari, A., Ghoshal, U., and Mittal, B. (2007). Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer. Cancer Detect Prev 31, 225-232.
15. Kang, S., Wang, D.J., Li, W.S., Wang, N., Zhou, R.M., Sun, D.L., Duan, Y.N., Li, S.Z., Li, X.F., and Li, Y. (2009). Association of p73 and MDM2 polymorphisms with the risk of epithelial ovarian cancer in Chinese women. Int J Gynecol Cancer 19, 572-577.
16. Larsson, P., Wijkstrom, H., Thorstenson, A., Adolfsson, J., Norming, U., Wiklund, P., Onelöv, E., and Steineck., G. (2003). A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years. Scand J Urol Nephrol 37, 195-201.
17. Lee, S.H., Shin, M.S., Park, W.S., Kim, S.Y., Dong, S.M., Pi, J.H., Lee, H.K., Kim, H.S., Jang, J.J., Kim, C.S., Kim, S.H., Lee, J.Y., and Yoo, N.J. (1999). Alterations of Fas (APO-1=CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res 59, 3068-3072.
18. Li, G., Zhai, X., Zhang, Z., Chamberlain, R.M., Spitz, M.R., and Wei, Q. (2006). MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. Carcinogenesis 27, 2028-2033.
19. Lum, S.S., Chua, H.W., Li, H., Li, W.F., Rao, N., Wei, J., Shao, Z., and Sabapathy, K. (2008). MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcino-genesis 29, 754-761.
20. Miller, S.A., Dykes, D.D., and Polesky, H.F. (1998). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16, 1215-1215
21. Mohanty, N.K. (2005). Cancer urinary bladder etiopathology and its management. Health Adm 17, 126-131.
22. Momand, J., and Zambetti, G.P. (1997). Mdm-2: "big brother" of p53. J Cell Biochem 64, 343-352.
23. Parekh, D.J., Bochner, B.H., and Dalbagni, G. (2006). Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. J Clin Oncol 24, 5519-5527.
24. Phang, B.H., Linn, Y.C., Li, H., and Sabapathy, K. (2008) MDM2 SNP309G allele decreases risk but does not affect onset age or survival of Chinese leukemia patients, Eur J Cancer 44, 760-766.
25. Sanyal, S., Festa, F., Sakano, S., Zhang, Z., Steineck, G., Norm-ing, U., Wijkström, H., Larsson, P., Kumar, R., and Hemminki, K. (2004). Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis 25, 729-734.
26. Singh, V., Rastogi, N., Mathur, N., Singh, K., and Singh, M.P. (2008). Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. AEP 18, 48-57.
27. Takagi, Y., Takashi, M., Koshikawa, T., and Ohshima, S. (2000). Immunohistochemical demonstration of cyclin D1 in bladder cancers as an inverse indicator of invasiveness but not an independent prognostic factor. Int J Urol 7, 366-372.
28. Takahashi, T., Tanaka, M., Inazawa, J., Abe, T., Suda, T., and Nagata, S. (1994). Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol 6, 1567-1574.
29. Wagner, U., Suess, K., Luginbuhl, T., Schmid, U., Ackermann, D., and Zellwegener, T. (1999). Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. J Pathol 188, 44-50.
30. Wang, L.E., Cheng, L., Spitz, M.R., and Wei, Q. (2003). Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. Lung Cancer 42, 1-8.
31. Xia, B., Yu, Y.H., Guo, Q.S., Li, X.Y., Jiang, L., and Li, J. (2005). Association of Fas-670 gene polymorphism with inflammatory bowel disease in Chinese patients. World J Gastroenterol 11, 415-417.